Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced NSCLC With EGFR Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06945705
What this trial is testing

A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR-sensitive Mutations and Brain Metastasis

Who this might be right for
NSCLC
Henan Cancer Hospital 146
Testing effectiveness (Phase 2)Looking for participantsNCT07070440
What this trial is testing

DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)

Who this might be right for
Non Small Cell Lung Cancer
Dizal Pharmaceuticals 180
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06752408
What this trial is testing

Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Peking Union Medical College Hospital 316
Early research (Phase 1)Study completedNCT04858958
What this trial is testing

Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation

Who this might be right for
NSCLC
Allist Pharmaceuticals, Inc. 90
Large-scale testing (Phase 3)Study completedNCT01953913
What this trial is testing

Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 542
Not applicableUnknownNCT05127382
What this trial is testing

Osimertinib as 1st Line Therapy for Patients With Advanced EGFR Positive Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer Non-small Cell Stage IV
Hellenic Cooperative Oncology Group 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07699952
What this trial is testing

First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) Alterations

Who this might be right for
Lung Cancer (NSCLC)EGFR Activating MutationHER2
Yongsheng Wang 35
Large-scale testing (Phase 3)UnknownNCT02387086
What this trial is testing

Gefitinib Combined With Thalidomide to Treat NSCLC

Who this might be right for
NSCLC
Bai Jun 380
Large-scale testing (Phase 3)Active Not RecruitingNCT04988295
What this trial is testing

Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 776
Large-scale testing (Phase 3)Study completedNCT01544179
What this trial is testing

IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 265
Testing effectiveness (Phase 2)UnknownNCT01391260
What this trial is testing

Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
ZhuGuangYing 30
Not applicableUnknownNCT03766490
What this trial is testing

Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer

Who this might be right for
Non-Small-Cell Lung
The First Affiliated Hospital of Soochow University 66
Testing effectiveness (Phase 2)Study completedNCT00891579
What this trial is testing

Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) Mutations

Who this might be right for
Non Small Cell Lung Cancer
Chinese Society of Lung Cancer 161
Testing effectiveness (Phase 2)Active Not RecruitingNCT05751187
What this trial is testing

Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients

Who this might be right for
Non-squamous NSCLC
Shanghai Chest Hospital 54
Testing effectiveness (Phase 2)Looking for participantsNCT07336732
What this trial is testing

Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

Who this might be right for
Non-Small-Cell Lung Cancer
Avistone Biotechnology Co., Ltd. 40
Not applicableStudy completedNCT04609319
What this trial is testing

Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review

Who this might be right for
Lung Cancer
Pfizer 307
Not applicableLooking for participantsNCT05559645
What this trial is testing

Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)

Who this might be right for
Non Small Cell Lung Cancer
Peking Union Medical College Hospital 180
Testing effectiveness (Phase 2)Study completedNCT01802632
What this trial is testing

AZD9291 First Time In Patients Ascending Dose Study

Who this might be right for
Advanced Non Small Cell Lung CancerAdvanced (Inoperable) Non Small Cell Lung Cancer
AstraZeneca 603
Early research (Phase 1)Looking for participantsNCT06641609
What this trial is testing

A Phase I Study of CFT8919 in Patients With Advanced NSCLC

Who this might be right for
Non-Small Cell Lung Cancer With EGFR Mutation
Betta Pharmaceuticals Co., Ltd. 166
Testing effectiveness (Phase 2)Active Not RecruitingNCT04619004
What this trial is testing

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer MetastaticNon-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Daiichi Sankyo 277
Next Page